VHH humanisation can be a challenge. Here, we compare two methods – safe-but-slow rational humanisation and fast-but-risky CDR grafting. We also explore the impact of synthetic versus immune-derived frameworks.
VHH Humanisation
read more
Technical Resources
A selection of technical resources.
Small and mighty – VHH ‘bolt-ons’ to expand therapeutic functionality
Small antibody building blocks: VHHs or “Nanobodies” are single domain antibodies about 1/10th the size of an IgG. Combined with their robust biophysical properties and high solubiltiy, the simplicity of these molecules…
The golden age of bi-specific antibodies is here
Bi-specific antibodies (BsAbs) – antibodies that can recognise two different epitopes on either the same or different antigens – have been around for a long time. However, in the past few years we’ve seen a renaissance in the design and application of these molecules.
On the Origin of VHHs: Student serendipity and coincidental camels
We explain how VHHs – small format single-domain antibody fragments – have a range of unique properties that make them ideal for enhancing the therapeutic potential of conventional IgG antibodies.
From monoclonals to bi-specifics: Harnessing the transformative power of VHHs to supercharge IgG therapeutics
We explain how VHHs – small format single-domain antibody fragments – have a range of unique properties that make them ideal for enhancing the therapeutic potential of conventional IgG antibodies.
CIS display, a DNA-based in vitro selection technology for therapeutic peptides
CIS display is a DNA-based in vitro display technology that enables the display and selection of peptides and proteins from extremely large libraries…
CIS display: In vitro selection of peptides from libraries of protein–DNA complexes
PNAS published February 23, 2004. 101 (9) 2806-2810
The structure of myeloid cell-specific TNF inhibitorsaffects their biological properties
Immunogenicity and humanization of single-domainantibodies
Nature publication: AAV delivery of VHH Intrabodies
De Genst et al showcase the AAV delivery and intracellular in vivo expression of Isogenica’s LlamdA™ VHHs in monomeric and bivalent forms. Interestingly, these VHHs display preferences for distinct...
Optimizing CAR-T and T-cell antibody engagers in haematological and solid tumours
A role for VHH single domain antibodies.
Isogenica’s PD-L1 VHH as Functional Antagonists
PD-1 is an immune checkpoint protein expressed on the surface of multiple types of immune cells, including antigen-stimulated T-cells and tumour specific T-cells1. Interaction between PD-1 and its...